Han Ling, Chen Yali, Zheng Ai, Chen Hengxi
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University No. 20, 3rd Section, South Renmin Road, Chengdu 610041, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education Chengdu 610041, Sichuan, China.
Am J Cancer Res. 2023 May 15;13(5):2126-2134. eCollection 2023.
In recent years, there has been increasing recognition of the relationship between neoadjuvant chemotherapy (NACT) in ovarian cancer and the incidence rate of venous thromboembolism (VTE). Some studies have suggested that NACT may be associated with a high risk of VTE in patients with ovarian cancer. To investigate this, we conducted a systematic review and meta-analysis of the incidence of VTE during NACT and its associated risk factors. We searched PubMed, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and the International Standard Randomized Controlled Trial Number Register (ISRCTN) from their inception to September 15, 2022. We calculated the incidence of VTE as the event rate (%) and used logistic regression analysis to investigate pooled VTE rates. Risk factors for VTE were presented as odds ratios (ORs), and pooled ORs was estimated using the inverse variance method. We reported pooled effect estimates with 95% confidence intervals (CIs). Our review included 7 cohort studies with 1244 participants. Meta-analysis of these studies revealed a pooled VTE rate of 13% during NACT (1224 participants; 95% CI, 9%-17%), with body mass index identified as a risk factor for VTE during NACT in 3 of the included studies (633 participants; OR, 1.76; 95% CI, 1.13-2.76).
近年来，卵巢癌新辅助化疗（NACT）与静脉血栓栓塞症（VTE）发病率之间的关系日益受到关注。一些研究表明，NACT可能与卵巢癌患者发生VTE的高风险相关。为了对此进行研究，我们对NACT期间VTE的发病率及其相关危险因素进行了系统评价和荟萃分析。我们检索了PubMed、Medline、Embase、Cochrane对照试验中心注册库（CENTRAL）、ClinicalTrials.gov以及国际标准随机对照试验编号注册库（ISRCTN），检索时间从各数据库建库至2022年9月15日。我们将VTE的发病率计算为事件发生率（%），并使用逻辑回归分析来研究合并的VTE发生率。VTE的危险因素以比值比（OR）表示，合并OR使用逆方差法估计。我们报告了合并效应估计值及其95%置信区间（CI）。我们的综述纳入了7项队列研究，共1244名参与者。对这些研究的荟萃分析显示，NACT期间合并的VTE发生率为13%（1224名参与者；95%CI为9%-17%），在纳入的3项研究（633名参与者）中，体重指数被确定为NACT期间VTE的一个危险因素（OR为1.76；95%CI为1.13-2.76）。
